Albuminuria: The kidney message on cardiovascular health

Journal of Hypertension

Volumn 34, Issue 3, 2016, Pages 399-400

  Viazzi, Francesca ^a   Pontremoli, Roberto ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE;

ALBUMINURIA; ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; BLOOD FLOW; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; LOW RISK PATIENT; MICROALBUMINURIA; NOTE; PREVALENCE; PRIORITY JOURNAL; PULSE WAVE; RENAL PROTECTION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY; KIDNEY DISEASE; RISK FACTOR;

ALBUMINURIA; CARDIOVASCULAR DISEASES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY DISEASES; RISK FACTORS;

EID: 84957574423     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000849     Document Type: Note

References (17)

1. Keen H, Chlouverakis C. An immunoassay method for urinary albumin at low concentrations. Lancet 1963; 2:913-914.
2. Viazzi F, Leoncini G, Conti N, Tomolillo C, Giachero G, Vercelli M, et al. Combined effect of albuminuria and estimated glomerular filtration rate on cardiovascular events and all-cause mortality in uncomplicated hypertensive patients. J Hypertens 2010; 28:848-855.
3. Viazzi F, Leoncini G, Conti N, Tomolillo C, Giachero G, Vercelli M, et al. Microalbuminuria is a predictor of chronic renal insufficiency in patients without diabetes and with hypertension: The MAGIC study. Clin J Am Soc Nephrol 2010; 5:1099-1106.
4. Pontremoli R. Microalbuminuria in essential hypertension-its relation to cardiovascular risk factors. Nephrol Dial Transplant 1996; 11:2113-2115.
5. Leoncini G, Ratto E, Viazzi F, Conti N, Falqui V, Parodi A, et al. Global risk stratification in primary hypertension: The role of the kidney. J Hypertens 2008; 26:427-432.
6. Savarese G, Dei Cas A, Rosano G, D'Amore C, Musella F, Mosca S, et al. Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients. A metaregression analysis of 32 randomized trials. Int J Cardiol 2014; 172:403-410.
7. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabet Care 2006; 29:595-600.
8. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Llosartan Intervention For Endpoint Reduction in Hypertension study. Hypertension 2005; 45:198-202.
9. Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, et al. ACCOMPLISH Investigators. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 2010; 56:77-85.
10. Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, et al. ACCOMPLISH Trial investigators. Renal outcomes with different fixeddose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): A prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375:1173-1181.
11. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547-553.
12. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al., ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1555.
13. Schmieder RE, Mann JF, Schumacher H, Gao P, Mancia G, Weber MA, et al., ONTARGET Investigators. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011; 22:1353-1364.
14. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al., Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
15. Tanaka F, Komi R, Makita S, Onoda T, Tanno K, Ohsawa M, et al. Low-grade albuminuria and incidence of cardiovascular disease and all-cause mortality in nondiabetic and normotensive individuals. J Hypertens 2016; 34:506-512.
16. Takase H, Sugiura T, Ohte N, Dohi Y. Urinary albumin as a marker of future blood pressure and hypertension in the general population. Medicine (Baltimore) 2015; 94:e511.
17. Leoncini G, Viazzi F, Pontremoli R. Overall health assessment: A renal perspective. Lancet 2010; 375:2053-2054.